Info

Genaissance is focused on integrating the use of human gene variation into the development of a new generation of DNA-based diagnostic and therapeutic products. The Company markets its HAPÔ Technology, clinical development skills and services to the pharmaceutical, biotechnology and diagnostic industry as the complete solution for improving the development, marketing and prescribing of drugs. Genaissance's core competency is predicting drug response. Genaissance, which was founded in 1997 and went public in August 2000, has product and service relationships with 16 of the top 20 pharmaceutical companies and offers its pharmaceutical and biotechnology customers one-stop shopping for all of their Pharmacogenomic needs. While Genaissance has focused on marketing its products and services to the pharmaceutical, biotechnology and diagnostic industry, the Company's HAPÔ Technology also has applications in other markets. Genaissance has agreements for using its technology and services not only with pharmaceutical, biotechnology and diagnostic companies but also with government and academic groups.